相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Polymorphism of the μ-Opioid Receptor Gene (OPRM1 118A>G) Affects Fentanyl-Induced Analgesia During Anesthesia and Recovery
Wei Dong Wu et al.
Molecular Diagnosis & Therapy (2012)
CYP2B6 and OPRM1 gene variations predict methadone-related deaths
Hannah Bunten et al.
ADDICTION BIOLOGY (2011)
Errors and reproducibility of DNA array-based detection of allelic variants in ADME genes: PHARMAchip™
Elisabet Cuyas et al.
PHARMACOGENOMICS (2010)
kappa-Opioid receptor signaling and brain reward function
Adrie W. Bruijnzeel
BRAIN RESEARCH REVIEWS (2009)
Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment
Mohammad-Reza Shiran et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance Part II
Shu-Feng Zhou
CLINICAL PHARMACOKINETICS (2009)
Promoting abstinence from cocaine and heroin with a methadone dose increase and a novel contingency
David H. Epstein et al.
DRUG AND ALCOHOL DEPENDENCE (2009)
Methadone-Nicotine Interactions in Methadone Maintenance Treatment Patients
Alexander K. Elkader et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
Major Depressive Disorder and Patient Satisfaction in Relation to Methadone Pharmacokinetics and Pharmacodynamics in Stabilized Methadone Maintenance Patients
Alexander K. Elkader et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution
Alexandra Doehring et al.
PHARMACOGENETICS AND GENOMICS (2009)
Persistence of heroin use despite methadone treatment: Poor coping self-efficacy predicts continued heroin use
Richard Senbanjo et al.
DRUG AND ALCOHOL REVIEW (2009)
Role of CYP2B6 in stereoselective human methadone metabolism
Rheem A. Totah et al.
ANESTHESIOLOGY (2008)
No influence of ABCB1 haplotypes on methadone dosage requirement
S. Crettol et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The Value of CYP2D6 and OPRM1 Pharmacogenetic Testing for Opioid Therapy
Kristen K. Reynolds et al.
CLINICS IN LABORATORY MEDICINE (2008)
CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme
Hongbing Wang et al.
CURRENT DRUG METABOLISM (2008)
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence
Orna Levran et al.
HUMAN MOLECULAR GENETICS (2008)
Interindividual variability of methadone response - Impact of genetic polymorphism
Yongfang Li et al.
MOLECULAR DIAGNOSIS & THERAPY (2008)
Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment
Amandeep Mann et al.
NEUROPHARMACOLOGY (2008)
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment
Severine Crettol et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2008)
Pharmacogenetic treatments for drug addiction: Alcohol and opiates
Colin N. Haile et al.
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE (2008)
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B6*6 and*26
Hiroyuki Gatanaga et al.
CLINICAL INFECTIOUS DISEASES (2007)
Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment
Jose Perez de los Cobos et al.
DRUG AND ALCOHOL DEPENDENCE (2007)
Enantiomeric metabolic interactions and stereoselective human methadone metabolism
Rheem A. Totah et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R, S)-methadone, LAAM and their main metabolites
Severine Crettol et al.
PHARMACOLOGY (2007)
ABCB1 and cytochrome P450 genotypes and phenotypes:: Influence on methadone plasma levels and response to treatment
Severine Crettol et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals
Janet K. Coller et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Predictors of retention in methadone programs: A signal detection analysis
Steven W. Villafranca et al.
DRUG AND ALCOHOL DEPENDENCE (2006)
CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients
Yannick Le Meur et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
One year outcomes for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS)
M Teesson et al.
DRUG AND ALCOHOL DEPENDENCE (2006)
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Jung-Won Suh et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002
J Bell et al.
DRUG AND ALCOHOL DEPENDENCE (2006)
Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1)
Danxin Wang et al.
AAPS JOURNAL (2006)
Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
S Crettol et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
DX Wang et al.
PHARMACOGENETICS AND GENOMICS (2005)
Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments
MJ Kreek et al.
PHARMACOLOGICAL REVIEWS (2005)
Genetics of the variable expression of CYP3A in humans
L Wojnowski
THERAPEUTIC DRUG MONITORING (2004)
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone
ED Kharasch et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction
V Yuferov et al.
PHARMACOGENETICS (2004)
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens
K Tsuchiya et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Diagnosing comorbid psychiatric disorders in substance abusers:: Validity of the Spanish versions of the psychiatric research interview for substance and mental disorders and the structured clinical interview for DSM-IV
M Torrens et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Subjective and physiological responses among racemicmethadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure
TB Mitchell et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease
P Klepstad et al.
ACTA ANAESTHESIOLOGICA SCANDINAVICA (2004)
Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19
JG Gerber et al.
CHIRALITY (2004)
A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment
MR Shiran et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro
JS Wang et al.
DRUG METABOLISM AND DISPOSITION (2003)
Chiral separation of methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrol (EDDP) and 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP) by capillary electrophoresis using cyclodextrin derivatives
T Kelly et al.
ELECTROPHORESIS (2003)
Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects
WE Evans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers
S Begré et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2002)
Retention rate and illicit opioid use during methadone maintenance interventions:: a meta-analysis
M Farré et al.
DRUG AND ALCOHOL DEPENDENCE (2002)
Summary of information on human CYP enzymes: Human P450 metabolism data
S Rendic
DRUG METABOLISM REVIEWS (2002)
The genetic determinants of the CYP3A5 polymorphism
E Hustert et al.
PHARMACOGENETICS (2001)
Patient satisfaction, use of services, and one-year outcomes in publicly funded substance abuse treatment
MJ Carlson et al.
PSYCHIATRIC SERVICES (2001)
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
T Lang et al.
PHARMACOGENETICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Cytochrome P450 2D6 genotype and methadone steady-state concentrations
CB Eap et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2001)
Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment
CB Eap et al.
DRUG AND ALCOHOL DEPENDENCE (2000)
Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility
K Wolff et al.
ADDICTION (2000)
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.
RE Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
